NO964742L - Behandling av atherosklerose og andre kardiovaskulære og inflammatoriske sykdommer - Google Patents

Behandling av atherosklerose og andre kardiovaskulære og inflammatoriske sykdommer

Info

Publication number
NO964742L
NO964742L NO964742A NO964742A NO964742L NO 964742 L NO964742 L NO 964742L NO 964742 A NO964742 A NO 964742A NO 964742 A NO964742 A NO 964742A NO 964742 L NO964742 L NO 964742L
Authority
NO
Norway
Prior art keywords
atherosclerosis
cardiovascular
treatment
inflammatory diseases
inflammatory
Prior art date
Application number
NO964742A
Other languages
English (en)
Other versions
NO964742D0 (no
Inventor
Russel M Medford
Alexander R Wayne
Sampath Parthasarathy
Bobby V Kahn
Margaret K Offermann
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of NO964742D0 publication Critical patent/NO964742D0/no
Publication of NO964742L publication Critical patent/NO964742L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/21—Radicals derived from sulfur analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/08—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/16—Salts of dithiocarbamic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
    • Y10T436/201666—Carboxylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
NO964742A 1994-05-10 1996-11-08 Behandling av atherosklerose og andre kardiovaskulære og inflammatoriske sykdommer NO964742L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24085894A 1994-05-10 1994-05-10
US08/317,399 US5807884A (en) 1992-10-30 1994-10-04 Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
PCT/US1995/005880 WO1995030415A1 (en) 1994-05-10 1995-05-10 Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

Publications (2)

Publication Number Publication Date
NO964742D0 NO964742D0 (no) 1996-11-08
NO964742L true NO964742L (no) 1996-11-08

Family

ID=26933783

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964742A NO964742L (no) 1994-05-10 1996-11-08 Behandling av atherosklerose og andre kardiovaskulære og inflammatoriske sykdommer

Country Status (17)

Country Link
US (6) US5807884A (no)
EP (1) EP0759752A4 (no)
JP (1) JP3120091B2 (no)
KR (1) KR100394157B1 (no)
CN (1) CN1152869A (no)
BG (1) BG101030A (no)
BR (1) BR9507716A (no)
CA (1) CA2189336A1 (no)
CZ (1) CZ330896A3 (no)
GE (1) GEP20012409B (no)
HU (1) HUT76728A (no)
MX (1) MX9605450A (no)
NO (1) NO964742L (no)
NZ (1) NZ287214A (no)
PL (2) PL180874B1 (no)
SK (1) SK136496A3 (no)
WO (1) WO1995030415A1 (no)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821260A (en) * 1992-10-30 1998-10-13 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
AUPM906594A0 (en) * 1994-10-26 1994-11-17 Peptide Technology Limited Synthetic polyunsaturated fatty acid analogues
US5571523A (en) * 1995-03-09 1996-11-05 President And Fellows Of Harvard College Antioxidant-induced apoptosis in vascular smooth muscle cells
US5741815A (en) * 1995-06-02 1998-04-21 Lai; Ching-San Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5792787A (en) * 1995-06-07 1998-08-11 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
NZ330475A (en) * 1996-09-20 1999-11-29 Univ Emory Antibodies, and use thereof in measuring lipid peroxidation in biological samples and method for inducing inflammation
JP2001505906A (ja) * 1996-12-10 2001-05-08 ハダジット メディカル リサーチ サービシズ アンド ディベラップメント カンパニー リミテッド 細胞の分化を誘導する血清由来因子およびその医薬的使用
GB2321455A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Lipophilic derivatives of biologically active compounds
ID23877A (id) * 1997-05-14 2000-05-25 Atherogenics Inc Senyawa-senyawa dan metode-metode untuk penghambatan ekspresi vcam-1
US6852878B2 (en) 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
EP1695959A1 (en) * 1997-05-14 2006-08-30 Atherogenics, Inc. Compouds and methods for the inhibition of the expression of VCAM-1
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
EA200000087A1 (ru) * 1997-07-01 2000-08-28 Атеродженикс, Инк. Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
IL122891A0 (en) * 1998-01-11 1998-08-16 Yeda Res & Dev Pharmaceutical compositions comprising a thiocarbamate
IL122892A0 (en) 1998-01-11 1998-08-16 Yeda Res & Dev Pharmaceutical compositions comprising a thiocarbamate
PL346762A1 (en) * 1998-07-06 2002-02-25 Guilford Pharm Inc Naaladase inhibitors useful as pharmaceutical compounds and compositions
CA2658200A1 (en) * 1998-07-06 2000-01-13 Mgi Gp, Inc. Naaladase inhibitors useful as pharmaceutical compounds and compositions
US6589987B2 (en) 1998-09-08 2003-07-08 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using tetraethyl thiuram disulfide
US6548540B2 (en) 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US7816403B2 (en) 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
US6706759B1 (en) 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US6887712B1 (en) 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
US6372187B1 (en) 1998-12-07 2002-04-16 Mcdermott Technology, Inc. Alkaline sorbent injection for mercury control
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
EP1153010A1 (en) 1999-02-08 2001-11-14 Checkpoint Genetics, Inc. $i(N)-SUBSTITUTED AMINO ACIDS, ANTIOXIDANT PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND METHODS USING SAME
US6855859B2 (en) * 1999-03-31 2005-02-15 The Babcock & Wilcox Company Method for controlling elemental mercury emissions
US6284199B1 (en) * 1999-03-31 2001-09-04 Mcdermott Technology, Inc. Apparatus for control of mercury
US6734192B1 (en) 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
US6710086B1 (en) * 2000-02-25 2004-03-23 Medinox, Inc. Protected forms of pharmacologically active agents and uses therefor
CA2403490A1 (en) 2000-03-21 2001-10-25 Atherogenics, Inc. N-substituted dithiocarbamates for the treatment of biological disorders
CA2404044A1 (en) 2000-04-11 2001-10-18 Atherogenics, Inc. Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
US7416726B2 (en) 2000-04-13 2008-08-26 The Rockefeller University Enhancement of antibody-mediated immune responses
AU2001296959A1 (en) * 2000-10-02 2002-04-15 Reddy Us Therapeutics, Inc Methods and compositions for the treatment of inflammatory diseases
EP1343502A2 (en) 2000-11-17 2003-09-17 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
EP2425841A1 (en) 2000-11-24 2012-03-07 Vascular Biogenics Ltd. Methods Employing and Compositions Containing Defined Oxidized Phospholipids for Prevention and Treatment of Atherosclerosis
NO20006008L (no) * 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
US7273712B2 (en) * 2000-12-29 2007-09-25 Reddy Us Therapeutics, Inc. Methods and compositions for detecting compounds that modulate inflammatory responses
AU2002249893B2 (en) 2001-01-02 2007-05-24 The Cleveland Clinic Foundation Myeloperoxidase, a risk indicator for cardiovascular disease
US6596708B1 (en) 2001-09-07 2003-07-22 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
US20050129680A1 (en) * 2001-09-17 2005-06-16 Paul Wentworth Antimicrobial activity of antibodies
US20040116350A1 (en) * 2001-09-17 2004-06-17 Paul Wentworth Jr Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies
US20040157280A1 (en) * 2001-09-17 2004-08-12 Paul Wentworth Antibody mediated ozone generation
JP2005516941A (ja) * 2001-12-19 2005-06-09 アセロジエニクス・インコーポレイテツド カルコン誘導体及び疾患を治療するためのそれらの使用
US20030147958A1 (en) * 2002-01-29 2003-08-07 Cheol-Hee Ahn Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
WO2004044582A2 (en) * 2002-11-14 2004-05-27 Novartis Ag Antibody- or neutrophil-mediated ozone generation
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
US20040265323A1 (en) * 2003-05-16 2004-12-30 Mccormick Beth A. Compositions comprising pathogen elicited epithelial chemoattractant (eicosanoid hepoxilin A3), inhibitors thereof and methods of use thereof
US7173129B2 (en) * 2003-06-06 2007-02-06 Athero Genics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
US20060025481A1 (en) * 2004-02-09 2006-02-02 Strange Matthew L Process for preparation of probucol derivatives and polymorphic forms thereof
US7294736B2 (en) * 2004-04-09 2007-11-13 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
US7271274B2 (en) 2004-04-20 2007-09-18 Ahterogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
EP1812793A4 (en) * 2004-11-15 2008-04-16 Quantomix Ltd DEVICE AND METHOD FOR ANALYZING A METAL CHANGING
US7345191B2 (en) * 2005-02-26 2008-03-18 Cambrex Charles City, Inc. Process for preparation of probucol derivatives
US8071545B2 (en) * 2005-03-15 2011-12-06 Lewis S. Coleman, Md, Inc. Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism
US7767710B2 (en) 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
KR100823533B1 (ko) 2007-02-27 2008-04-30 바이오스펙트럼 주식회사 알파 비사볼올을 유효성분으로 포함하는 피부 상태 개선용조성물
JP2010522762A (ja) * 2007-03-26 2010-07-08 サルトリア・フアーマシユーテイカルズ・エル・エル・シー 糖尿病の治療のための方法及びプロブコール誘導体の組成物
US20080280985A1 (en) * 2007-03-27 2008-11-13 Scott Robert A D Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
EP2381940A4 (en) * 2008-11-26 2012-12-05 Univ Texas NEW FAMILY OF PAIN-PRODUCING SUBSTANCES AND METHOD FOR THE PRODUCTION OF NEW ANALGETICS
CN102250045A (zh) * 2010-05-21 2011-11-23 复旦大学附属华山医院 抗结核分支杆菌的化合物及其应用
WO2012040656A2 (en) * 2010-09-24 2012-03-29 Sciclone Pharmaceuticals, Inc. Biomarkers to track response to scv-07
US9029342B2 (en) 2012-09-17 2015-05-12 Board Of Regents Of The University Of Texas System Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof
KR101834469B1 (ko) * 2013-08-07 2018-03-06 알렉시온 파마슈티칼스, 인코포레이티드 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질
CN109232278A (zh) 2013-11-15 2019-01-18 Ds生物制药有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
US10905062B2 (en) * 2015-10-19 2021-02-02 General Mills, Inc. High protein oat species
RU2662316C1 (ru) * 2017-08-31 2018-07-25 Сергей Владимирович Кунгурцев Жидкофазная композиция с повышенным содержанием природных устойчивых к окислению омега-3 полинепредельных жирных кислот
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875170A (en) * 1971-05-25 1975-04-01 Banyu Pharma Co Ltd Pyridine bis (dithiocarbamate) derivatives
US4025527A (en) * 1973-07-13 1977-05-24 Smith Kline & French Laboratories Limited Certain thiazoles and oxazoles
GB1542840A (en) * 1975-02-03 1979-03-28 Smith Kline French Lab Heterocyclic dithiocarbamates and isothioureas
US4670471A (en) * 1981-11-03 1987-06-02 Clark Lealand L Treatment for inflammatory skin disease
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8421039D0 (en) * 1984-08-17 1984-09-19 Wyeth John & Brother Ltd Heterocyclic compounds
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
EP0228458B2 (en) * 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
EP0284879A3 (en) * 1987-03-17 1990-10-17 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US4870101A (en) * 1987-03-17 1989-09-26 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
US5035878A (en) * 1988-09-12 1991-07-30 University Of Rochester Use of dithiocarbamates to counteract myelosuppression
US5166133A (en) * 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
JPH07501204A (ja) * 1991-06-28 1995-02-09 マサチューセッツ インスティテュート オブ テクノロジー 局所的オリゴヌクレオチド療法
FR2679452B1 (fr) * 1991-07-22 1993-11-12 Cis Bio International Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation.
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5380747A (en) * 1992-10-30 1995-01-10 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5792787A (en) * 1995-06-07 1998-08-11 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases

Also Published As

Publication number Publication date
WO1995030415A1 (en) 1995-11-16
EP0759752A1 (en) 1997-03-05
HU9603041D0 (en) 1997-01-28
US5807884A (en) 1998-09-15
US5750351A (en) 1998-05-12
MX9605450A (es) 1997-12-31
CZ330896A3 (cs) 1998-07-15
PL184466B1 (pl) 2002-11-29
GEP20012409B (en) 2001-04-25
NZ287214A (en) 2001-05-25
KR100394157B1 (ko) 2004-02-11
US5773209A (en) 1998-06-30
BG101030A (en) 1997-09-30
CN1152869A (zh) 1997-06-25
JP3120091B2 (ja) 2000-12-25
US5811449A (en) 1998-09-22
US5846959A (en) 1998-12-08
US5773231A (en) 1998-06-30
JPH10500111A (ja) 1998-01-06
PL180874B1 (pl) 2001-04-30
NO964742D0 (no) 1996-11-08
CA2189336A1 (en) 1995-11-16
SK136496A3 (en) 1999-01-11
PL317193A1 (en) 1997-03-17
HUT76728A (en) 1997-11-28
EP0759752A4 (en) 2001-08-08
BR9507716A (pt) 1997-09-23

Similar Documents

Publication Publication Date Title
NO964742D0 (no) Behandling av atherosklerose og andre kardiovaskulære og inflammatoriske sykdommer
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
NO943663L (no) Forbindelser som kan anvendes for behandling av allergiske sykdommer og betennelsessykdommer
NO992641D0 (no) Blandinger og fremgangsmÕter for behandling eller forhindring av betennelsessykdommer
NO974365L (no) Fremgangsmåte og krystallformer av 2-metyl-thieno-benzodiazepin
NO933240D0 (no) Anordning ved og fremstilling av tannb!rste
NO894296L (no) Fremgangsmaate for behandling av leddgikt og betennelsessykdommer.
NO20002784D0 (no) Forhindring og behandling av amyloidogen sykdom
NO970373D0 (no) Benzoksazoler og pyridinderivater anvendelige ved behandling av type-II-diabetes
NO962179L (no) Fremgangsmåte for fremstilling av metallocen og anvendelse derav
NO971015D0 (no) Forbindelser og metoder for behandling av cancer
NO985896D0 (no) Behandling av urininkontinens ved bruk av (S)-oksybutynin og (S)-desetyloksybutynin
NO971900D0 (no) Blandinger og behandling av multippel sklerose
DK21995A (da) Forbinding og fremgangsmade til fremstilling af forbinding
NO965563D0 (no) Behandling og profylakse av osteoporese
IS3718A7 (is) Amínóbenzodiazepines og aðferð til framleiðslu þess
IS3792A7 (is) Benzodiazepinones og aðferð til framleiðslu þess
NO177731C (no) F¶rprodukt og fremgangsmÕte for fremstilling av samme
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer
NO961808D0 (no) Konstruksjon og produksjon av vaksine
NO971419L (no) Fremgangsmåte for fremstilling av 1,3-alkendioler og 3-hydroksyaldehyder
NO990018D0 (no) Belegg og fremgangsmÕte for fremstilling derav
NO951932L (no) Behandling av infertilitet og forökning av fertiliseringskapasiteter
FI951494A0 (fi) Jyvien käsittely laajentimella
KR950702532A (ko) 말레인아미드산, 그 에스테르 및 말레이미드의 제조방법

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application